0

506128

PARNAXLAB

img img img img
No Data Available

PARNAX LAB LTD. Share Price Update

As of the latest trading session, PARNAX LAB LTD. share price is currently at ₹114.9, which is down by ₹-7.75 from its previous closing. Today, the stock has fluctuated between ₹114.75 and ₹126.25. Over the past year, PARNAX LAB LTD. has achieved a return of 38.21%. In the last month alone, the return has been -4.98%.

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

PARNAX LAB LTD. fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    136.90

  • P/E Ratio (TTM)

    101.69

  • Beta

    0.48

  • Book Value / share

    20.26

  • Return on equity

    5.00%

  • EPS (TTM)

    1.19

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.71

info icon alternate text

PARNAX LAB LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 2.71
Operating Expense 1.95
Net Profit 0.71
Net Profit Margin (%) 26.19
Earnings Per Share (EPS) 0.62
EBITDA 0.97
Effective Tax Rate (%) 25.26
Particulars SEP 2025 (Values in Cr)
Revenue 1.70
Operating Expense 1.24
Net Profit 0.49
Net Profit Margin (%) 28.82
Earnings Per Share (EPS) 0.43
EBITDA 0.70
Effective Tax Rate (%) 25.75
Particulars JUN 2025 (Values in Cr)
Revenue 1.97
Operating Expense 1.84
Net Profit 0.23
Net Profit Margin (%) 11.67
Earnings Per Share (EPS) 0.20
EBITDA 0.34
Effective Tax Rate (%) 25.80
Particulars MAR 2025 (Values in Cr)
Revenue 0.84
Operating Expense 1.14
Net Profit -0.08
Net Profit Margin (%) -9.52
Earnings Per Share (EPS) -0.07
EBITDA -0.08
Effective Tax Rate (%) 27.27
Particulars DEC 2024 (Values in Cr)
Revenue 0.99
Operating Expense 0.95
Net Profit 0.16
Net Profit Margin (%) 16.16
Earnings Per Share (EPS) 0.14
EBITDA 0.24
Effective Tax Rate (%) 23.80
Particulars MAR 2025 (Values in Cr)
Revenue 7.02
Operating Expense 5.86
Net Profit 1.39
Net Profit Margin (%) 19.80
Earnings Per Share (EPS) 1.21
EBITDA 1.94
Effective Tax Rate (%) 24.73
Particulars MAR 2024 (Values in Cr)
Revenue 7.44
Operating Expense 5.52
Net Profit 1.82
Net Profit Margin (%) 24.46
Earnings Per Share (EPS) 1.59
EBITDA 2.65
Effective Tax Rate (%) 25.30
Particulars MAR 2023 (Values in Cr)
Revenue 7.47
Operating Expense 6.22
Net Profit 1.20
Net Profit Margin (%) 16.06
Earnings Per Share (EPS) 1.09
EBITDA 1.95
Effective Tax Rate (%) 25.76
Particulars MAR 2022 (Values in Cr)
Revenue 7.15
Operating Expense 6.54
Net Profit 0.54
Net Profit Margin (%) 7.55
Earnings Per Share (EPS) 0.64
EBITDA 1.53
Effective Tax Rate (%) 30.76
Particulars MAR 2021 (Values in Cr)
Revenue 2.37
Operating Expense 3.69
Net Profit -1.13
Net Profit Margin (%) -47.67
Earnings Per Share (EPS) -1.33
EBITDA -0.38
Effective Tax Rate (%) 9.60
Particulars MAR 2025 (Values in Cr)
Book Value / Share 72.35
ROE % 14.92
ROCE % 13.77
Total Debt to Total Equity 0.97
EBITDA Margin 15.15
Particulars MAR 2024 (Values in Cr)
Book Value / Share 62.32
ROE % 14.39
ROCE % 12.87
Total Debt to Total Equity 1.01
EBITDA Margin 12.91
Particulars MAR 2023 (Values in Cr)
Book Value / Share 54.11
ROE % 15.64
ROCE % 14.66
Total Debt to Total Equity 1.12
EBITDA Margin 14.18
Particulars MAR 2022 (Values in Cr)
Book Value / Share 47.24
ROE % 20.47
ROCE % 16.71
Total Debt to Total Equity 1.59
EBITDA Margin 14.33
Particulars MAR 2021 (Values in Cr)
Book Value / Share 38.26
ROE % -1.13
ROCE % 5.67
Total Debt to Total Equity 1.69
EBITDA Margin 11.27
Particulars MAR 2025 (Values in Cr)
Book Value / Share 19.63
ROE % 5.00
ROCE % 6.72
Total Debt to Total Equity 0.00
EBITDA Margin 27.64
Particulars MAR 2024 (Values in Cr)
Book Value / Share 18.42
ROE % 6.54
ROCE % 9.09
Total Debt to Total Equity 0.03
EBITDA Margin 35.62
Particulars MAR 2023 (Values in Cr)
Book Value / Share 16.85
ROE % 4.77
ROCE % 6.18
Total Debt to Total Equity 0.32
EBITDA Margin 25.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.14
ROE % 3.98
ROCE % 6.24
Total Debt to Total Equity 1.18
EBITDA Margin 21.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 5.54
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.13
EBITDA Margin -16.03
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.68
Total Assets 189.81
Total Liabilities 189.81
Total Equity 83.24
Share Outstanding 1
Price to Book Ratio 5.45
Return on Assets (%) 6.06
Return on Capital (%) 8.01
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.87
Total Assets 190.26
Total Liabilities 190.26
Total Equity 71.69
Share Outstanding 1
Price to Book Ratio 7.03
Return on Assets (%) 5.05
Return on Capital (%) 6.73
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.78
Total Assets 145.07
Total Liabilities 145.07
Total Equity 62.26
Share Outstanding 1
Price to Book Ratio 3.09
Return on Assets (%) 5.94
Return on Capital (%) 7.62
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5.78
Total Assets 153.46
Total Liabilities 153.46
Total Equity 48.27
Share Outstanding 0
Price to Book Ratio 11.82
Return on Assets (%) 5.37
Return on Capital (%) 7.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.26
Total Assets 106.25
Total Liabilities 106.25
Total Equity 32.62
Share Outstanding 0
Price to Book Ratio 3.52
Return on Assets (%) -0.34
Return on Capital (%) -0.41
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.27
Total Assets 24.71
Total Liabilities 24.71
Total Equity 22.54
Share Outstanding 1
Price to Book Ratio 5.45
Return on Assets (%) 5.64
Return on Capital (%) 6.19
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.45
Total Assets 22.23
Total Liabilities 22.23
Total Equity 21.15
Share Outstanding 1
Price to Book Ratio 7.03
Return on Assets (%) 8.20
Return on Capital (%) 8.62
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.28
Total Assets 21.36
Total Liabilities 21.36
Total Equity 19.35
Share Outstanding 1
Price to Book Ratio 3.09
Return on Assets (%) 5.63
Return on Capital (%) 5.9
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 4.34
Total Assets 23.53
Total Liabilities 23.53
Total Equity 12.74
Share Outstanding 0
Price to Book Ratio 11.82
Return on Assets (%) 2.30
Return on Capital (%) 2.47
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.11
Total Assets 17.64
Total Liabilities 17.64
Total Equity 4.71
Share Outstanding 0
Price to Book Ratio 3.52
Return on Assets (%) -6.41
Return on Capital (%) -7.02
Particulars MAR 2025 (Values in Cr)
Net Income 15.67
Cash from Operations 35.04
Cash from Investing -16.39
Cash from Financing -15.81
Net change in Cash 0.09
Free Cash Flow 44.79
Particulars MAR 2024 (Values in Cr)
Net Income 12.04
Cash from Operations 18.51
Cash from Investing -31.51
Cash from Financing 14.81
Net change in Cash -0.82
Free Cash Flow 32.65
Particulars MAR 2023 (Values in Cr)
Net Income 12.27
Cash from Operations 23.77
Cash from Investing -9.92
Cash from Financing -14.06
Net change in Cash -3.08
Free Cash Flow 35.05
Particulars MAR 2022 (Values in Cr)
Net Income 12.26
Cash from Operations 8.78
Cash from Investing -16.49
Cash from Financing 12.13
Net change in Cash 4.18
Free Cash Flow 26.61
Particulars MAR 2021 (Values in Cr)
Net Income -0.08
Cash from Operations 7.06
Cash from Investing -6.56
Cash from Financing 0.05
Net change in Cash -0.20
Free Cash Flow 11.61
Particulars MAR 2025 (Values in Cr)
Net Income 1.85
Cash from Operations 0.30
Cash from Investing -0.19
Cash from Financing -0.02
Net change in Cash 0.06
Free Cash Flow 0.30
Particulars MAR 2024 (Values in Cr)
Net Income 2.44
Cash from Operations 0.09
Cash from Investing 0.30
Cash from Financing -1.21
Net change in Cash -0.82
Free Cash Flow 0.21
Particulars MAR 2023 (Values in Cr)
Net Income 1.62
Cash from Operations -0.26
Cash from Investing 0.13
Cash from Financing -2.92
Net change in Cash -3.06
Free Cash Flow -0.21
Particulars MAR 2022 (Values in Cr)
Net Income 0.77
Cash from Operations -0.35
Cash from Investing 0.00
Cash from Financing 4.59
Net change in Cash 4.23
Free Cash Flow -0.35
Particulars MAR 2021 (Values in Cr)
Net Income -1.25
Cash from Operations 0.47
Cash from Investing 0.00
Cash from Financing -0.47
Net change in Cash 0.00
Free Cash Flow 0.47
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 28.41 12.30 1.47 217.72 23.12 42.00
BLISS GVS PHARMA LTD 201.65 19.28 1.88 2133.23 105.05 244.05
CIPLA LTD 1298.80 22.07 3.18 104914.55 1283.00 1672.20
FERMENTA BIOTECH LIMITED 339.00 11.28 2.55 997.71 241.30 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 28.41 27.32 3.96 217.72 23.12 42.00
AMRUTANJAN HEALTH CARE LTD. 528.05 26.40 4.46 1526.63 522.15 789.95
ASTRAZENECA PHARMA INDIA LTD. 8358.20 100.45 26.15 20895.50 6501.60 10653.05
BLISS GVS PHARMA LTD 201.65 27.47 1.93 2133.23 105.05 244.05

PARNAX LAB LTD. shareholding pattern

Holding

27.7%
72.29%
9.41%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

PARNAX LAB LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
119.15 -0.70 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 124.50
  • 26 Days 125.80
  • 10 Days 126.00
  • 50 Days 124.80
  • 12 Days 126.20
  • 100 Days 124.20
  • 20 Days 126.10
  • 200 Days 122.60
122.48 PIVOT

First Support

116.07

First Resistance

126.42

Second Support

112.13

Second Resistance

132.83

Third Support

105.72

Third Resistance

136.77

RSI

42.55

ADX

19.67

MACD

0.45

Williams % R

-89.97

Commodity Channel Index (CCI)

-163.71

Date

2026-03-16

Week

2116.00

Same Day

2405.00

Month

4800.00

1 Year

0.49

3 Year

0.64

Over 1 Month

-4.98%

down

Over 1 Year

38.21%

down

Over 3 Months

-5.66%

down

Over 3 Years

25.99%

down

Over 6 Months

-13.26%

down

Over 5 Years

40.65%

down

PARNAX LAB LTD. Corporate Actions

Top Gainers

PARNAX LAB LTD. Share Price

Parnax Lab Limited, formerly Known as Krishna Deep Trade & Investment Limited was incorporated in August, 1982. The Company changed the name from Krishna Deep Trade & Investment Ltd to Parnax Lab Limited with effect from July 19, 2012. The Company engages in the business activities of manufacturing and export of Pharmaceutical Formulations. Initially, it was engaged in investment and financing activities.

Naxpar Pharma Private Limited is Subsidiary Company of the Holding Company. With over two decades of rich experience behind it, the Naxpar Group is at the helm of innovation in the manufacturing of Pharmaceuticals, Cosmetics, Herbal/Ayurvedic formulations & Nutraceuticals (FSSAI) products. The Naxpar Group is headquartered in Mumbai, India. It is as a result of their diligence and perseverance that Naxpar's prowess in pharmaceutical manufacturing has seen exponential growth and achievement, significant milestones such as the coveted ISO 9002 status from RWTUV, Germany for following Good Quality Systems in manufacturing and marketing of formulations for domestic and international markets. Naxpar initially began as a single-establishment - indicative of its resounding success and growing client base, the Company has state-of-the-art accredited manufacturing facilities with high speed packing lines in Silvassa, in Dadra & Nagar Haveli and Baddi in Himachal Pradesh.

Naxpar's key strength is manufacturing finished formulations for multinationals in India and abroad and in emerging pharmaceutical markets such as Nigeria, Kazakhstan, Kenya, Mauritius etc. The WHO-approved and EHS-compliant Company is now well placed to venture into markets such as South East Asia, CIS, LatAm etc. where it is keen to establish its presence as a leading pharmaceuticals, cosmetics and herbal products manufacturer.

Parent organization Indian Private
NSE symbol [-]
Founded 1982
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Parnax Lab Ltd?

Answer Field

Parnax Lab Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 119.15 as on Mar 23 2026 10:45 AM.

What is the Market Cap of Parnax Lab Ltd Share?

Answer Field

The market cap of Parnax Lab Ltd for NSE ₹ 0.00 & for BSE ₹ 136.90 as on Mar 23 2026 10:45 AM.

What is the 52 Week High and Low of Parnax Lab Ltd?

Answer Field

The 52 Week High and Low of Parnax Lab Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 145.00 and ₹ 85.60.

What is 1 year return for Parnax Lab Ltd?

Answer Field

The 1 year returns on the stock has been 38.21%.

What is the P/E Ratio of Parnax Lab Ltd Share?

Answer Field

As on Mar 23 2026 10:45 AM the price-to-earnings (PE) ratio for Parnax Lab Ltd share is 101.69.

What is the PB ratio of Parnax Lab Ltd Share?

Answer Field

As on Mar 23 2026 10:45 AM, the price-to-book (PB) ratio for Parnax Lab Ltd share is 20.26.

How to Buy Parnax Lab Ltd Share?

Answer Field

You can trade in Parnax Lab Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Parnax Lab Ltd Share on Bajaj Broking App?

Answer Field

To buy Parnax Lab Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Parnax Lab Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59